Neuropsychiatric and Cognitive Deficits in Parkinson’s Disease and Their Modeling in Rodents
Open Access
- 17 June 2021
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 9 (6) , 684
Abstract
Parkinson’s disease (PD) is associated with a large burden of non-motor symptoms including olfactory and autonomic dysfunction, as well as neuropsychiatric (depression, anxiety, apathy) and cognitive disorders (executive dysfunctions, memory and learning impairments). Some of these non-motor symptoms may precede the onset of motor symptoms by several years, and they significantly worsen during the course of the disease. The lack of systematic improvement of these non-motor features by dopamine replacement therapy underlines their multifactorial origin, with an involvement of monoaminergic and cholinergic systems, as well as alpha-synuclein pathology in frontal and limbic cortical circuits. Here we describe mood and neuropsychiatric disorders in PD and review their occurrence in rodent models of PD. Altogether, toxin-based rodent models of PD indicate a significant but non-exclusive contribution of mesencephalic dopaminergic loss in anxiety, apathy, and depressive-like behaviors, as well as in learning and memory deficits. Gene-based models display significant deficits in learning and memory, as well as executive functions, highlighting the contribution of alpha-synuclein pathology to these non-motor deficits. Collectively, neuropsychiatric and cognitive deficits are recapitulated to some extent in rodent models, providing partial but nevertheless useful options to understand the pathophysiology of non-motor symptoms and develop therapeutic options for these debilitating symptoms of PD.Keywords
This publication has 200 references indexed in Scilit:
- Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral VectorsPLOS ONE, 2013
- Age-Dependent Effects of A53T Alpha-Synuclein on Behavior and Dopaminergic FunctionPLOS ONE, 2013
- Pramipexole-Induced Increased Probabilistic Discounting: Comparison Between a Rodent Model of Parkinson's Disease and ControlsNeuropsychopharmacology, 2012
- Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive ControlBiological Psychiatry, 2011
- Contributions of Striatal Dopamine Signaling to the Modulation of Cognitive FlexibilityBiological Psychiatry, 2011
- Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouseBehavioural Brain Research, 2010
- Mice expressing the A53T mutant form of human alpha‐synuclein exhibit hyperactivity and reduced anxiety‐like behaviorJournal of Neuroscience Research, 2010
- Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromesProceedings of the National Academy of Sciences, 2009
- Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's diseaseMovement Disorders, 2009
- Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injuryNeurobiology of Disease, 2008